NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
FDA asks the public to weigh in on ibogaine clinical studies; Gabon wants its cut of the ibogaine boom
Plus: The risks and benefits of five psychedelics; and Scholar argues for more religious perspectives in psychedelic studies
The Future of Psychedelics Is in the Living Room
Welcome to The Psychedelic Blog. A bestselling publication exploring altered states & the culture surrounding them.
Sticking it to insomnia: AI-powered forehead patch tracks brain signals to help boost deep sleep
A patch the size of a Band-Aid, stuck to your forehead, can now do something no traditional sleep study or fitness tracker can: nudge your brain toward a better night's sleep. William Coon, a sleep scientist at the Jo...
Three minutes: a man’s death on mushrooms, and a ruling his fiancée won't accept
Should dispensaries have warnings about risks?
The Greek Who Unglued Me from My Adjectives
In celebration of Anne Carson’s Nobel Prize for Literature
New Mexico Medical Psilocybin Program Regulation Changes Spark Outcry
Clinicians, advocates and lawmakers rebuked the New Mexico Health Department over restrictive draft psilocybin-assisted therapy rules. The post New Mexico Medical Psilocybin Program Regulation Changes Spark Outcry fir...
Citizens Commission on Human Rights International urged the FDA not to approve psychedelic drugs for mental disorders or emotional distress, citing risks including aggression and psychosis.
Citizens Commission on Human Rights International submitted comments opposing approval of psilocybin, LSD, DMT, mescaline and other psychedelics for mental disorders or emotional distress. It called for strict limits ...
Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
FDA Floats Ibogaine Trial Design, Asks Field for Input On Monday, the day FDA’s Considerations for Potential Future Therapeutic Use of Psychedelic Drugs public comment period closed, the agency issued a request for in...
World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of…
Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study (NCT07391332, psilocybin)
This Phase II, randomised, double-blind trial (n=30) will evaluate the feasibility and preliminary efficacy of psilocybin-assisted psychotherapy for individuals diagnosed with gambling disorder. Participants will be a...
Filament Health has licensed and will supply PEX010 for a UCSF Phase 2 trial testing a single psilocybin dose for methamphetamine use disorder among people with HIV.
The quadruple-blinded trial will enrol 30 participants at Zuckerberg San Francisco General Hospital, comparing single 25 mg and 5 mg doses of PEX010. It is expected to begin in November 2026, with primary outcomes cov...
LSD treatment affects working memory-related brain function in patients with major depressive disorder
This reanalysis of a randomised double-blind trial (n=43) compared two low-dose (25 µg) with two higher-dose (100 and 200 µg) LSD treatments in people with major depressive disorder (MDD). Higher-dose LSD increased br...
Psychedelics restructure information in the human brain
This brain imaging reanalysis (n=80) compared information processing across five compounds: LSD, psilocybin, ketamine, DMT and 5-MeO-DMT. The authors found changes in information storage, transfer and transformation t...
Beyond the substance: A systematic review of psychological treatment frameworks in psychedelic-assisted therapy
This systematic review (2026) of 44 clinical trials (1,537 participants) examined psychological treatment frameworks accompanying psilocybin, LSD and DMT for psychiatric symptoms. Most trials used preparation, dosing ...
Psychedelics restructure information in the human brain
This brain imaging reanalysis (n=80) compared information processing across five compounds: LSD, psilocybin, ketamine, DMT and 5-MeO-DMT. The authors found changes in information storage, transfer and transformation t...